Applied Therapeutics (APLT) announced its late-breaking abstract for govorestat, or AT-007, has been selected for oral presentation at the Peripheral Nerve Society 2025 Annual Meeting, held May 17-20. The presentation will include full 12-month clinical results from the INSPIRE Phase 3 trial in SORD Deficiency, a subtype of Charcot-Marie-Tooth disease. It will also include new topline 18-month and 24-month data. The company previously shared topline 12-month data in February 2024.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics Reports 2024 Financial Results and Leadership Changes
- Applied Therapeutics reports FY24 EPS (76c), consensus ($1.33)
- Applied Therapeutics Delays Yearly Report Filing
- Applied Therapeutics files Form 12b-25 with SEC
- Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer